We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101
News

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101
News

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Can-Fite BioPharma has announced that its 75-patient Phase II clinical study with CF101 to treat patients with moderate to severe Psoriasis has successfully met its primary objectives.

Patients in this double-blind study were randomly assigned to 1, 2 or 4 mg of CF101 or placebo twice daily. The drug was taken orally as a monotherapy for 12 weeks. By several analyses, the patient group receiving 2 mg CF101 (n=17) demonstrated statistically significant improvement in Psoriasis Activity and Severity Index (PASI) scores, the standard method of disease assessment and the primary efficacy endpoint in this trial.

The group receiving 2 mg twice daily showed dramatic improvement in mean PASI score, relative to baseline, after 12 weeks of treatment (p<0.0001).

Furthermore, this group’s improvement was statistically significantly superior to the placebo group results (p = 0.03). 83% of the 2 mg group patients demonstrated improvement in disease parameters upon CF101 treatment and 35% demonstrated an improvement of over 50% (“PASI 50”). Improvement was progressive over time and regression analysis suggests that longer treatment will result in continued amelioration of the disease symptoms.

Dr. Michael David, Head of the Department of Dermatology, Rabin Medical Center, the study principal investigator said: “The study data is impressive and promising. CF101 is a unique small molecule orally bioavailable drug with an impressive safety profile based on accumulated experience in more than 700 patients. There is a market need in Psoriasis for small molecule drugs and I am confident that Can Fite should progress with the clinical development of CF101 based on the study data.”

CF101 was safe and well tolerated during the study period. This important safety result adds to the drug’s remarkable safety record from past studies in more than 700 patients.

The success in this study adds up to the success in a recently announced clinical study in dry eye patients. In both these studies the patients were treated with CF101 as a stand-alone treatment. Psoriasis, as well as dry eye disease are inflammatory diseases. The success in both these studies points to the potential general efficacy of CF101 in treatment of inflammatory diseases, with very large market potential.

Furthermore and most importantly success in these studies validates the technology platform of the company.
Advertisement